(Q44659386)

5 December 2017

title

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia (English)

1 reference

5 December 2017

1 reference

Wassim McHayleh

1

1 reference

5 December 2017

Kenneth Foon

2

1 reference

5 December 2017

Robert Redner

3

1 reference

5 December 2017

Rajesh Sehgal

4

1 reference

5 December 2017

Anastasios Raptis

5

1 reference

5 December 2017

Mounzer Agha

6

1 reference

5 December 2017

The Minh Luong

7

1 reference

5 December 2017

James J Schlesselman

8

1 reference

5 December 2017

Michael Boyiadzis

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

5 December 2017

1 reference

5 December 2017

volume

116

1 reference

5 December 2017

issue

12

1 reference

5 December 2017

page(s)

3001-3005

1 reference

Targeting treatment in AML.

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

The difficult problem of acute myeloid leukemia in the older adult

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Age and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Grup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25078

7 January 2021

Identifiers

DOI

10.1002/CNCR.25078

1 reference

5 December 2017

1 reference